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Background: Canine vector-borne diseases (CVBD) are caused by a diverse array of pathogens with varying
biological behaviors that result in a wide spectrum of clinical presentations and laboratory abnormalities. For many
reasons, the diagnosis of canine vector-borne infectious diseases can be challenging for clinicians. The aim of the
present study was to compare CVBD serological and molecular testing as the two most common methodologies
used for screening healthy dogs or diagnosing sick dogs in which a vector-borne disease is suspected.
Methods: We used serological (Anaplasma species, Babesia canis, Bartonella henselae, Bartonella vinsonii subspecies
berkhoffii, Borrelia burgdorferi, Ehrlichia canis, and SFG Rickettsia) and molecular assays to assess for exposure to, or
infection with, 10 genera of organisms that cause CVBDs (Anaplasma, Babesia, Bartonella, Borrelia, Ehrlichia,
Francisella, hemotropic Mycoplasma, Neorickettsia, Rickettsia, and Dirofilaria). Paired serum and EDTA blood samples
from 30 clinically healthy dogs (Group I) and from 69 sick dogs suspected of having one or more canine vector-borne
diseases (Groups II-IV), were tested in parallel to establish exposure to or infection with the specific CVBDs targeted
in this study.
Results: Among all dogs tested (Groups I-IV), the molecular prevalences for individual CVBD pathogens ranged
between 23.3 and 39.1%. Similarly, pathogen-specific seroprevalences ranged from 43.3% to 59.4% among healthy and
sick dogs (Groups I-IV). Among these representative sample groupings, a panel combining serological and
molecular assays run in parallel resulted in a 4-58% increase in the recognition of exposure to or infection with CVBD.
Conclusions: We conclude that serological and PCR assays should be used in parallel to maximize CVBD diagnosis.
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When dogs develop clinical and hematological abnormal-
ities, such as fever, cytopenias, hypoalbuminemia, hyper-
globulinemia, polyarthritis or protein-losing nephropathy,
veterinarians will often include vector-borne diseases
among the differential diagnoses. In North America the
number of recognized CVBDs has increased and now
includes anaplasmosis (Anaplasma phagocytophilum or
Anaplasma platys), babesiosis (Babesia canis and Babesia
gibsoni), bartonellosis (numerous Bartonella sp.), heart-
worm disease (Dirofilaria immitis), ehrlichiosis (Ehrlichia
canis, Ehrlichia chaffeensis, Ehrlichia ewingii, or Ehrlichia* Correspondence: rgmaggi@ncsu.edu
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unless otherwise stated.muris), hepatozoonosis (Hepatozoon canis and Hepatozoon
americanum), Lyme disease (Borrelia burgdorferi), tu-
laremia (Francisella tularensis), hemotropic Mycoplasma
(multiple Mycoplasma sp.), Potomac Horse Fever (Neorick-
ettsia risticii), and Rocky Mountain spotted fever (Rickettsia
rickettsii). In addition, CVBDs such as E. ewingii and E.
chaffeensis appear to have increased in incidence and geo-
graphic distribution due to the spread of Ambylomma
americanum ticks northward throughout much of the
United States. Also, B. gibsoni, which is frequently found in
American Pitbull Terriers, can be transmitted directly to
other dogs via fighting and bites from an infected animal
[1] thus, this historically vector-borne pathogen can be dir-
ectly transmitted among dogs. Although the mode(s) of
transmission are incompletely understood, several Barto-
nella species are thought to be transmitted to dogs by fleasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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evolving appreciation of the role of CVBDs as a cause of
disease in dogs. As the optimal treatment modalities differ
for these diseases, it behooves veterinarians to choose
CVBD diagnostic tests wisely, so as to economically and ac-
curately evaluate exposure to and/or infection with a
spectrum of vector-borne pathogens.
All diagnostic tests have inherent advantages and limi-
tations. Serology relies on an immunologically appropri-
ate and diagnostically detectable host immune response
against one or more CVBD pathogens. As antibodies
can persist for variable intervals after a pathogen is
immunologically or therapeutically eliminated, serology
does not confirm active or persistent infection in the
patient, which is a diagnostic disadvantage. However,
serology can be used to retrospectively confirm recent
infection, by demonstrating seroconversion (i.e. a four-
fold change in the patient’s antibody titer between acute
and convalescent serum samples) [1]. The persistence of
circulating antibodies can also be an advantage of ser-
ology in that antibodies may be detectable during
chronic intravascular CVBD infections, when a pathogen
may be circulating below the limit of PCR detection or
sequestered in tissues that are not routinely submitted
for PCR testing. Another potential limitation of serology
includes diminished specificity, due to antibody cross-
reactivity within or between CVBD genera [2-8]. Never-
theless, cross-reactivity between Anaplasma, Bartonella,
Ehrlichia, and Rickettsia genera in dogs seems to be very
unlikely, as dogs experimentally-infected with these
pathogens develop very specific antibodies that do not
cross react among genera [9-15].
Conversely, serological antigens chosen or available for
assays may be too specific or mismatched to the etiological
pathogens resulting in false negative results. These factors
can result in the inability to accurately identify the infect-
ing species or strain, which can have therapeutic impli-
cations for the patient. A technical limitation for the
development of some CVBD serological assays is the in-
ability to produce antigens in sufficient quantities to be
used in indirect fluorescent antibody (IFA) or enzyme-
linked immunoabsorbent assays (ELISA) (examples in-
clude A. platys, E. ewingii, Babesia and Hepatozoon spp.),
although the use of synthetic peptides may help overcome
this limitation. With the advent of PCR testing, it has also
become obvious that some dogs do not mount a detect-
able antibody response, despite persistent intravascular in-
fection with CVBD pathogens [16-20].
Similar to serology, PCR has advantages and disadvan-
tages for the diagnosis of CVBDs. PCR has the distinct
advantage over serology of detecting “active” infection in
a single sample from a single time-point. Additionally,
PCR can be used to specifically target a pathogen at the
species or strain level by using different PCR primer setsor by sequencing PCR products. While some a priori
knowledge or assumptions about the DNA sequence of
a pathogen are needed to design PCR-based assays, PCR
does not require definitive knowledge of the pathogen
DNA sequence. Additionally, PCR does not require that
the pathogen(s) be isolated or their antigens produced to
achieve the development and validation of an assay.
Multiple pathogens or species can be detected using
multiplex PCR assays [21-23] but these assays can be
more challenging in the context of achieving optimal
sensitivity for all pathogens targeted in the panel. Co-
infecting pathogens may cause competition in the PCR
reaction process [24,25]. Substantially higher concen-
trations of one pathogen compared to the other(s) can
result in detection of only one organism despite the
presence of a co-infection. The main limitation to PCR
testing is the requirement for adequate template (nucleic
acid of the target organism) in the patient sample to
achieve amplification of the target DNA sequence. For
vector-borne pathogens such as Anaplasma spp., B.
burgdorferi, and Bartonella spp., it is well documented
that the number of intravascular organisms fluctuates
over time following transmission [10,11,13,14]; therefore,
PCR testing at a single time point may produce a false
negative result for an infected patient. Some other tech-
nical disadvantages of PCR-based testing include poten-
tial false negative results due to the presence of PCR
inhibitors that were not removed during the nucleic acid
purification process and the potential for laboratory con-
tamination resulting in false positive reactions in pa-
tients that are not infected. The latter disadvantages can
be minimized by the use of appropriate techniques, re-
agents and the incorporation of appropriate controls.
Unless mechanisms are developed to overcome all of the
limitations of PCR-based testing, PCR is unlikely to
serve as a stand-alone assay for the diagnosis of many
vector-borne infections.
In the current study, a panel of serological assays was
compared to multiple PCR assays using samples from
healthy dogs and dogs suspected of being infected with
one or more CVBDs.
Methods
Sample group selection
Paired serum and ethylenediaminetetraacetic acid (EDTA)-
anti-coagulated blood samples from several defined groups
of sick dogs were selected from a convenience sample of
diagnostic accessions of the Vector-Borne Disease Diag-
nostic Laboratory (VBDDL), at the College of Veterinary
Medicine, North Carolina State University. To facilitate a
comparative analysis between serology and PCR, all patient
samples were tested in parallel and in an identical manner,
regardless of the test(s) originally requested by the attend-
ing clinician. In addition, paired serum and EDTA samples
Maggi et al. Parasites & Vectors 2014, 7:127 Page 3 of 9
http://www.parasitesandvectors.com/content/7/1/127retrieved from storage at -80°C from 30 clinically
healthy dogs examined during routine wellness appoint-
ments (Group I) were tested to establish background
exposure to or infection with the defined population of
CVBDs targeted in this study. Samples from 69 sick
dogs (Groups II-IV) were selected on the basis of prior
serology or PCR results. Group II consisted of 20 sick
dog sample sets submitted by attending veterinarians
from which no antibodies were detected using the ser-
ology panel defined below. The attending veterinarian
for these cases only requested serologic testing. PCR
was performed retrospectively (as described below).
Group III consisted of 25 sample sets from sick dogs that
were seroreactive to at least one vector-borne pathogen.
The attending veterinarian for these cases only requested
serologic testing and PCR was performed retrospectively
(as described below).
Group IV consisted of sample sets from 24 sick dogs
that were previously PCR positive for Babesia, Bartonella,
Ehrlichia, Anaplasma or Rickettsia species. The attending
veterinarian for these cases only requested PCR testing
(for one or more organisms). Both serologic testing and
PCR testing, including testing for additional organisms (as
described below) were performed retrospectively.
Serology
For this study, all serum samples were tested using a com-
mercial ELISA based kita and by IFA assays using a panel
of VBDDL antigens. All antigens were grown in vitro or,
in the case of B. canis, in vivo by personnel in the VBDDL
using strains of canine or feline origin. Briefly, antibody re-
sponses to B. canis, Bartonella henselae, Bartonella vinso-
nii subspecies berkhoffii, E. canis and spotted fever group
Rickettsia were tested by traditional IFA practices with
fluorescein conjugated goat anti-dog IgG (Thermo Fisher
Scientifics, Waltham MA 02452) [14].
Serum samples were diluted in phosphate buffered saline
(PBS) solution containing 1% normal goat serum, 0.05%
Tween-20 and 0.5% powdered nonfat dry milk (BioRad,
Hercules, CA) to block non-specific antigen binding sites
[15]. Seropositive samples were defined as having endpoint
titers ≥ 1:64 using a twofold scale of 1:16 – 1:8192. Dirofi-
laria immitis antigen, as well as antibodies to Anaplasma
spp., Ehrlichia spp. and the C6 peptide of B. burgdorferi,
were detected using a commercial in-house ELISA-based
kit according to manufacturer’s instructions. Serum from
the healthy dog population had been previously tested
using a version of the ELISA kitb which did not contain
Anaplasma spp. antigens. Due to limited serum, results for
these dogs were not determined for Anaplasma spp.
PCR testing
Following selection of samples for the various groups
(Groups I-IV), all EDTA-anti-coagulated blood sampleswere randomized and tested in an operator blinded
fashion. Ten microbial genera (Anaplasma, Babesia,
Bartonella, Borrelia, Ehrlichia, Francisella, hemotropic
Mycoplasma, Neorickettsia, Rickettsia, and Dirofilaria)
were targeted using specific PCR assays as previously re-
ported [16-22]. To further assess potential infection with
Dilofilaria spp. PCR amplification of Wolbachia spp.
was used as additional indirect evidence to support a
diagnosis of canine heartworm disease [21-23]. In all
cases in which blood samples were PCR positive, direct
DNA sequencing was performed. Reference sequences
for this study included the following GenBank acces-
sion numbers: AY055469 (Anaplasma phagocytophilum),
M82801 (A. platys), AY072925 (B. canis vogeli), AY618928
(large unnamed Babesia sp. “coco”) AF271081 (B. gibsoni),
NC_005956.1 (Bartonella henselae Houston I), AF369529
(Bartonella henselae SA2), DQ059763 (B. vinsonii subsp.
berkhoffii genotype II), DQ059764 (B. vinsonii subsp. ber-
khoffii genotype III), AF312490 (B. koehlerae), NC_007354
(Ehrlichia canis), NR_044747 (E. ewingii), AY529641
(Mycoplasma haemocanis), GQ129113 (M. haematopar-
vum) and CP000848 (Rickettsia rickettsii). Sequences were
compared to the GenBank database using the Basic Local
Alignment Search Tool.
Statistical analysis
Agreement between PCR-based assays and serological
assays was assessed by calculating an un-weighted kappa
statistic using a statistical program.c For agreement be-
tween PCR and serological assays for Anaplasma, the
detection of any Anaplasma sp. by PCR was considered
a positive result and the detection of a colorimetric
change in the Anaplasma ELISA was considered a posi-
tive result. For agreement between PCR and serological
assays for Babesia, the detection of any Babesia sp. by
PCR was considered a positive result and the detection
of an antibody titer ≥ 1:64 against B. canis was consid-
ered a positive result. For agreement between PCR and
serological assays for Bartonella, the detection of any
Bartonella sp. by PCR was considered a positive result
and the detection of an antibody titer ≥ 1:64 against any
Bartonella sp. was considered a positive result. For
agreement between PCR and serological assays for
Ehrlichia, the detection of any Ehrlichia sp. by PCR was
considered a positive result and the detection of an
antibody titer ≥ 1:64 against E. canis or a colorimetric
change in the Ehrlichia spp. ELISA was considered a
positive result. For agreement between PCR and sero-
logical assays for Rickettsia, the detection of any Rickettsia
sp. by PCR was considered a positive result and the detec-
tion of an antibody titer ≥ 1:64 against R. rickettsii was
considered a positive result. Agreement between PCR-
based assays and serological assays could not be calculated
for Borrelia spp., Dirofilaria sp. or Mycoplasma spp.
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0.40 indicated fair agreement, 0.41–0.60 indicated moder-
ate agreement, 0.61–0.80 indicated strong agreement, and
0.81–1 indicated almost perfect agreement.
Results
The overall agreement between PCR and serology test
results for dogs in Groups I to IV are summarized in
Table 1. The number of serology versus PCR positive
dogs within each Group for each pathogen is summa-
rized in Table 2. Molecular and serological results for
each pathogen and for each dog in each group are de-
tailed in Tables 3, 4, 5 and 6. DNA of Neorickettsia,
Wolbachia and Francisella spp. was not PCR amplified,
from any dog in the study.
Group I: clinically healthy dogs
Of the 30 Group I healthy dog blood samples, 16 had no
evidence of infection with or exposure to CVBDs
(Table 3). Combined serological and molecular testing
identified exposure to or infection with CVBDs in 14
healthy dogs. Thirteen dogs were seroreactive (antibody
titer ≥ 1:64) to one (n = 12) or more (n = 1) antigens by
IFA testing. No healthy dog was IFA seroreactive to B.
canis, or B. vinsoni subsp berkhoffii antigens. One, six,
and seven dogs were seroreactive to E. canis, B. henselae
or R. rickettsii antigens, respectively. All 30 Group I dogs
were negative by ELISA, including the one E. canis IFA
seroreactor. Based upon PCR amplification and DNA
sequencing, 6 dogs were infected with B. henselae, of
which only two were B. henselae seroreactive. Three R.
rickettsii seroreactors were PCR positive for B. henselae,
one of which was also E. canis seroreactive. One dog
was PCR positive for Mycoplasma haemocanis. This dog
was seroreactive against B. henselae antigens but did not
have detectable Bartonella DNA in its blood.
Group II: sick dogs in which CVBD antibodies were not
detected and for which no PCR testing had been
requested
Nineteen of 20 Group II sick dogs had no evidence of
infection with or exposure to CVBDs (Table 4). The
remaining dog was PCR positive for B. gibsoni and sero-
negative to all antigens tested. Babesia gibsoni IFA test-
ing was not performed as a component of this study.Table 1 Overall agreement between PCR and serology test re
Group Dogs Positive by PCR (%) Po
I 30 7 (23.3)
II 20 1 (5)
III 25 2 (8)
IV 24 24 (100)Group III: sick dogs in which CVBD antibodies against at
least one pathogen were detected and for which no PCR
testing had been requested
Of the 25 dogs in Group III, two dogs were PCR positive
(Table 5). One dog was actively infected with R. rickettsii
based upon PCR and DNA sequencing and was seroreac-
tive against R. rickettsii with a titer of 1:128. The other dog
had antibodies against B. burgdorferi and Anaplasma spp.
detected by ELISA and was PCR positive for Mycoplasma
haemocanis. All eight E. canis IFA seroreactive dogs were
positive by ELISA; however, none were PCR positive. Six
dogs were seroreactive to B. henselae antigens and one to
B. vinsonii subsp. berkhoffii antigens, but were not Barto-
nella PCR positive.Group IV: sick dogs from which DNA of at least one CVBD
pathogen was detected by PCR testing, but serological
testing had not been requested
Group IV, consisted of 24 dogs that were previously
PCR positive with Ehrlichia, Anaplasma, Babesia or
Bartonella spp. When serological and PCR assays were
performed beyond the PCR requested by the attending
clinician exposure to or infection with additional CVBD
of different genera were identified in 13 dogs (Table 6).Comparative serological and molecular testing
For the PCR assays requested by the attending veterinar-
ian there was complete agreement between VBDDL PCR
results and repeat blinded testing. Overall, the agree-
ment between PCR and serology ranged from 28.6% for
the healthy dogs to 4 - 50% for sick dogs depending on
groups (Table 1). The agreement between PCR and ser-
ology depended greatly on the tested species. There was
strong agreement (kappa: 0.637, 95% CI 0.453-0.822) be-
tween PCR-based assays and serological assays for Babe-
sia spp. There was moderate agreement (kappa: 0.353,
95% CI 0.117-0.589) between PCR-based assays and
serological assays for Anaplasma spp. There was moder-
ate agreement (kappa: 0.289, 95% CI 0.130-0.447) be-
tween PCR-based assays and serological assays for
Ehrlichia spp. There was poor agreement (kappa: 0.111,
95% CI -0.081-0.304) between PCR-based assays and
serological assays for Bartonella spp. There was poor
agreement (kappa: 0.069, 95% CI -0.003-0.141) between
PCR-based assays and serological assays for R. rickettsii.sults for Groups I to IV
sitive by Serology (%) Agreement between positives (%)
13 (43.3) 2/14 (28.6)
0 (0) 0/1 (0)
25 (100) 1/25 (4)
17 (70.8) 12/24 (50)
Table 2 Number of seropositive (Ser) or PCR positive dogs within each Group for each pathogen
Group Dogs Babesia Bartonella Rickettsia Ehrlichia Anaplasma Borrelia Dilofilaria
tested Ser-PCR Ser-PCR Ser-PCR Ser-PCR Ser-PCR Ser-PCR Ser-PCR
I 30 0-0 [0] 6-6 [2] 7-0 [0] 1-0 [0] N/A 0-0 [0] 0-0 [0]
II 20 0-1 [0] 0-0 [0] 0-0 [0] 0-0 [0] 0-0 [0] 0-0 [0] 0-0 [0]
III 25 0-0 [0] 6-0 [0] 12-1 [1] 8-0 [0] 3-0 [0] 4-0 [0] 0-0 [0]
IV 24 6-11 [6] 6-6 [1] 2-0 [0] 4-4 [3] 2-5 [2] 3-0 [0] 1-0 [0]
Number of dogs positive for both serology and PCR (agreement) are listed between brackets.
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For all three Babesia spp. (B. canis, B. gibsoni and the
large unnamed Babesia sp.), DNA sequencing analyses
documented identities between 99 and 100%, when com-
pared to our reference sequences. Sequencing analysis
identified Anaplasma and Ehrlichia spp. identities be-
tween 99.7-100% when compared to reference sequences.
Infection with R. rickettsii was confirmed in one dog
(100% identity to reference sequence). B. henselae, B. koeh-
lerae and B. vinsonii subsp. berkhoffii DNA had 100%
identity with reference sequences. Both cases of hemotro-
pic Mycoplasma sp. shared 100% sequence identity with
our reference sequence.
Discussion
Development of DNA amplification techniques or other
molecular approaches by which CVBD pathogens can be
detected and identified to the species or strain level in
diagnostic samples continues to facilitate a more rationalTable 3 IPRL PCR and serology of thirty healthy dogs (Group
Sample # IPRL PCR Babesia spp. Bartonella spp. Rickettsia
1 BhSA2 Neg Neg Pos
2 BhSA2 Neg Neg Pos
3 BhSA2 Neg Neg Pos
4 BhHI Neg Pos Neg
5 BhHI Neg Pos Neg
6 BhSA2 Neg Neg Neg
7 Mhc Neg Pos Neg
8 Neg Neg Pos Neg
9 Neg Neg Pos Neg
10 Neg QNS Pos Neg
11 Neg Neg Neg Pos
12 Neg Neg Neg Pos
13 Neg Neg Neg Pos
14 Neg Neg Neg Pos
15 Neg Neg Neg Neg
16-30 Neg Neg Neg Neg
Abbreviations: IPRL Intracellular Pathogens Research Laboratory, BhHI Bartonella hen
Mhc Mycoplasma haemocanis.basis for selection of treatment modalities. However, from
a diagnostic perspective, it does not appear that either
PCR or serological assays alone are adequate to identify
infection or exposure in every case (Table 2). The results
of this study demonstrate that evidence of exposure to or
infection with vector-borne pathogens in dogs can be in-
creased by using a combination of serological and PCR-
based assays in parallel. Use of such comprehensive testing
not only resulted in detection of exposure or infection
with CVBD pathogens in a greater number of dogs, it also
resulted in the identification of co-infections that would
have been missed if only one testing method was used.
While the antibiotic treatment history and the rationale
for the submission of each sample (other than the healthy
control group) was not known, each group of dogs is likely
to represent a scenario in which clinical, therapeutic or
public health decisions are likely to be different had the
clinician submitted for both PCR and serological assays
in parallel.I) from North Carolina
Serology

















selae Houston I, BhSA2 Bartonella henselae San Antonio 2,
Table 4 IPRL PCR assay results in twenty sick dogs (Group II) that were IFA and Snap® 4DX kit seronegative in the
VBDDL
Serology
Sample # IPRL PCR Babesia spp Bartonella spp Rickettsia spp. Ehrlichia spp. Anaplasma spp. Borrelia burgdorferi Dirofilaria immitis
#1 B. gib Neg Neg Neg Neg Neg Neg Neg
#2 to #20 Neg Neg Neg Neg Neg Neg Neg Neg
Abbreviations: IPRL Intracellular Pathogens Research Laboratory, VBDDL Vector-Borne Diseases Diagnostic Laboratory, B.gib Babesia gibsoni.
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similar to those being screened as blood donors. De-
pending on individual hospital blood donor screening
practices (Rickettsia, Borrelia or Dirofilaria exposure or
infection are not typically included as exclusion criterion
for canine blood donors), the use of PCR and serological
assays in parallel increased the number of donors that
could be excluded to 33% (10/30) compared to 23% (7/30)
if either PCR or serology were used alone.Table 5 IPRL PCR assay results for twenty five sick dogs (Grou
VBDDL
Sample # IPRL PCR Babesia spp Bartonella spp Rickettsia spp. Ehr
1 R. rickettsii Neg Neg Pos
2 Mhc Neg Neg Neg
3 Neg Neg Neg Neg
4 Neg Neg Neg Neg
5 Neg Neg Neg Neg
6 Neg Neg Neg Neg
7 Neg Neg Pos Neg
8 Neg Neg Pos Neg
9 Neg Neg Neg Neg
10 Neg Neg Neg Pos
11 Neg Neg Neg Pos
12 Neg Neg Neg Pos
13 Neg Neg Pos Pos
14 Neg Neg Pos Pos
15 Neg Neg Neg Pos
16 Neg Neg Neg Pos
17 Neg Neg Neg Pos
18 Neg Neg Pos Pos
19 Neg Neg Neg Pos
20 Neg Neg Neg Pos
21 Neg Neg Pos Neg
22 Neg Neg Neg Neg
23 Neg Neg Neg Neg
24 Neg Neg Neg Neg
25 Neg Neg Neg Neg
Abbreviations: IPRL Intracellular Pathogens Research Laboratory, VBDDL Vector-Borne
R. rickettsii Rickettsia rickettsii.Group II (sick dogs in which CVBD antibodies were not
detected and for which no PCR testing had been re-
quested) represents a population of dogs for which only
serological assays were requested by the attending veterin-
arian. It seems plausible to assume that after the requested
testing these dogs were considered less likely to be infected
with or exposed to CVBD. However, the use of PCR and
serological assays in parallel would have facilitated the
identification of an infection in 5% (1/20) of those cases.p III) that were IFA or Snap® 4DX kit positive in the
Serology
lichia spp. Anaplasma spp. Borrelia burgdorferi Dirofilaria immitis
Neg Neg Neg Neg
Neg Pos Pos Neg
Pos Neg Neg Neg
Pos Neg Neg Neg
Pos Neg Neg Neg
Pos Neg Neg Neg
Pos Neg Neg Neg
Pos Neg Neg Neg
Pos Neg Neg Neg
Pos Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Neg Neg
Neg Neg Pos Neg
Neg Neg Pos Neg
Neg Neg Pos Neg
Neg Pos Neg Neg
Neg Pos Neg Neg
Diseases Diagnostic Laboratory, hc Mycoplasma haemocanis;
Table 6 IPRL PCR and serology assays results for twenty four dogs (Group IV) that were PCR positive based upon prior


















1 A.ph & B.gib Neg Neg Pos Neg Pos Pos Neg
2 A.ph Neg Neg Neg Neg Pos Pos Neg
3 A.ph Neg Neg Neg Neg Neg Pos Neg
4 A.pl Neg Neg Neg Neg Neg Neg Neg
5 E.canis & B.canis Pos Neg Neg Pos Neg Neg Pos
6 E.canis Neg Pos Neg Pos Neg Neg Neg
7 E.ew Neg Neg Neg Pos Neg Neg Neg
8 E.ew Neg Neg Neg Neg Neg Neg Neg
9 B.canis Neg Pos Neg Neg Neg Neg Neg
10 B.canis Pos Pos Neg Neg Neg Neg Neg
11 B.canis Neg Neg Neg Neg Neg Neg Neg
12 B.canis/B. coco Neg Neg Pos Neg Neg Neg Neg
13 B.coco Neg Neg Neg Pos Neg Neg Neg
14 B.gib Pos Neg Neg Neg Neg Neg Neg
15 B.gib Pos Pos Neg Neg Neg Neg Neg
16 B.gib Pos Neg Neg Neg Neg Neg Neg
17 B.gib Pos Pos Neg Neg Neg Neg Neg
18 BvbII Neg Pos Neg Neg Neg Neg Neg
19 BvbIII Neg Neg Neg Neg Neg Neg Neg
20 Bk Neg Neg Neg Neg Neg Neg Neg
21 Bk & Apl Neg Neg Neg Neg Neg Neg Neg
22 BhHI Neg Neg Neg Neg Neg Neg Neg
23 BhHI Neg Neg Neg Neg Neg Neg Neg
24 Bart sp Neg Pos Pos Pos Neg Neg Neg
Abbreviations: IPRL Intracellular Pathogens Research Laboratory, VBDDL Vector-Borne Diseases Diagnostic Laboratory, A.ph Anaplasma phagocytophilum,
A.pl Anaplasma platys, E.canis Ehrlichia canis, E.ew Ehrlichia ewingii, B.canis Babesia canis, B.coco Large unnamed Babesia sp. , B.gib Babesia gibsoni,
BvbII Bartonella vinsonii subspecies berkhoffii Genotype II, BvbIII Bartonella vinsonii subspecies berkhoffii Genotype III, Bk Bartonella koehlerae, BhHI Bartonella
henselae Houston I, BhSA2 Bartonella henselae San Antonio 2, Bart sp Bartonella species, unable to sequence.
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against at least one pathogen were detected and for
which no PCR testing had been requested) represents a
population of dogs for which only serological assays
were requested by the attending veterinarian. The
addition of PCR testing facilitated the identification of
an additional organism in 4% (1/25) of these cases. It is
also interesting to consider that if these clinicians had
only selected PCR assays, exposure to CVBD would have
been missed in 92% (23/25) of the cases.
Group IV (sick dogs from which DNA of at least one
CVBD pathogen was detected by PCR testing, but sero-
logical testing had not been requested) represents a
population of dogs for which only one or more PCR
assay(s) were requested by the attending veterinarian.
The use of more extensive PCR testing and serological
assays would have identified exposure to or infectionwith additional CVBD (i.e. potential co-infections) in
54% (13/24) of the cases. Additionally, if the attending
clinician had only requested serological assays on these
samples, exposure to or infection with additional CVBD
(i.e. potential co-infections) that would alter the case
management would have either been missed in 58% (14/24)
of cases, or CVBD would have been missed entirely in 13%
(3/24) of the cases. Examples where the identification
would alter the case management include a dog that had
antibodies against B. canis but was actually PCR positive
for B. gibsoni (i.e. Group IV #14 or #16) or a dog that had
evidence of infection with A. phagocytophilum and B. burg-
dorferi and exposure to or infection with R. rickettsii but
was also PCR positive for B. gibsoni. In some cases the add-
itional information would not have changed case manage-
ment. An example of such is the dog that was IFA
seroreactive against E. canis yet PCR positive for E. ewingii.
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upon seroreactivity, but would have been indicated on the
basis of the PCR result.
There are several specific reasons for lack of agree-
ment between PCR-based and serological assays, but dif-
ferences in sensitivity and specificity between assays are
of primary importance for interpretation. Specific exam-
ples that will result in differences include timing of sam-
ple collection, biological behavior of the pathogen and
variation in host immune responses to antigens. As our
understanding of CVBD and individual host responses
to infection increases it is becoming clearer that our cur-
rently available diagnostic assays all have shortcomings.
Conclusions
Cumulatively, the results of this study suggest that the
use of PCR and serological assays in parallel is likely to
increase the detection of infection with or exposure to
CVBDs. This clinical scenario is not unknown to the
veterinary profession. For example, veterinarians are
comfortable accepting that a multi-modal approach, in-
cluding antigen and antibody testing combined with
diagnostic imaging, is ideal to diagnose feline heartworm
infection [26]. However, it is important to note that the
increased detection of infection with or exposure to
CVBD does not always confirm disease causation and
the attending veterinarian is still responsible for inter-
pretation of test results in light of the patient’s clinical
signs, laboratory abnormalities and response to treat-
ment. Clinicians must consider the prevalence of each
sign or laboratory abnormality with each type of infec-
tion and a failure to respond to appropriate treatment
should prompt the consideration of alternative diagno-
ses. In conclusion, it still appears that an ultimate test
for the diagnosis of CVBDs remains elusive. To optimize
clinical decision making, clinicians should consider using
panels that include serological and PCR assays in parallel
to maximize their chances of detecting infection or ex-
posure to CVBD pathogens.
Endnotes
aSnap® 4DX kit, IDEXX Laboratories Inc., Westbrook,
Maine; bSnap® 3DX kit, IDEXX Laboratories Inc., Westbrook,
Maine; cWinEpiscope 2.0, http://www.clive.ed.ac.uk/.
Abbreviation
CVBD: Canine vector-borne diseases; IFA: Indirect fluorescent antibody;
ELISA: Enzyme-linked immunoabsorbent assays; VBDDL: Vector-Borne Disease
Diagnostic Laboratory; IPRL: Intracellular Pathogens Research Laboratory.
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